Study of Mosunetuzumab Combined With DA EPOCH Chemotherapy for Untreated High-Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma with c-Myc Rearrangement

What this Trial Is About

Researchers are evaluating the safety, side effects, and effectiveness of mosunetuzumab combined with chemotherapy in patients with untreated, c-Myc rearrangement positive, high-grade B cell lymphoma or diffuse large B cell lymphoma. This phase IbII clinical trial focuses on previously untreated patients with specific genetic lymphoma types, aiming to assess how well this combination treatment works and how tolerable it is. Participants receive mosunetuzumab intravenously on days 1, 8, and 15 of the first cycle, and on day 1 of following cycles. Chemotherapy drugs including etoposide, doxorubicin, vincristine, cyclophosphamide, and prednisone are given on specific days within each 21-day cycle, for up to 6 cycles. The study involves bone marrow aspirations, tumor biopsies, and various scans such as PET, CT, MRI, echocardiography, or MUGA, performed at screening and throughout treatment. During the study, participants undergo regular blood tests and imaging to monitor treatment response and side effects. After completing treatment, follow-up visits occur every three months for two years, then every six months for three more years. Researchers measure outcomes like dose-limiting toxicities, complete response rates, overall response, progression-free survival, and overall survival, with safety and treatment details closely tracked.

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma